J 2024

Real Clinical Effectiveness of Molnupiravir Against 30-day Mortality Among 74 541 SARS-CoV-2-Positive Patients: A Nationwide Cohort Study From the Czech Republic

PAVLÍK, Tomáš; Jiří JARKOVSKÝ; Ondřej ŠANCA; Martina KOZIAR VASAKOVA; Pavel DLOUHY et. al.

Basic information

Original name

Real Clinical Effectiveness of Molnupiravir Against 30-day Mortality Among 74 541 SARS-CoV-2-Positive Patients: A Nationwide Cohort Study From the Czech Republic

Authors

PAVLÍK, Tomáš; Jiří JARKOVSKÝ; Ondřej ŠANCA; Martina KOZIAR VASAKOVA; Pavel DLOUHY; Vladimir CERNY; Petr ŠTOURAČ; Vlastimil VÁLEK and Ladislav DUŠEK

Edition

OPEN FORUM INFECTIOUS DISEASES, CARY, OXFORD UNIV PRESS INC, 2024, 2328-8957

Other information

Language

English

Type of outcome

Article in a journal

Country of publisher

United States of America

Confidentiality degree

is not subject to a state or trade secret

References:

URL

Organization

Lékařská fakulta – Repository – Repository

DOI

http://dx.doi.org/10.1093/ofid/ofae685

UT WoS

001374759800001

EID Scopus

2-s2.0-85212131397

Keywords in English

30-day all-cause mortality; COVID-19; COVID-19-related mortality; molnupiravir; SARS-CoV-2 infection

Links

LX22NPO5101, research and development project.
Changed: 7/2/2025 00:50, RNDr. Daniel Jakubík

Abstract

V originále

lt; .001). The effect of molnupiravir was highly significant regardless of sex, Deyo-Charlson Comorbidity Index score, hospitalization status, COVID-19 vaccination status, and patients older than age 65 years. Conclusions. In this cohort study, early initiation of molnupiravir was associated with a significant reduction in 30-day all-cause and COVID-19-related mortality in adult SARS-CoV-2 positive patients.
Displayed: 5/8/2025 05:22